Rubric Capital Management LP Purchases New Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Rubric Capital Management LP bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 293,083 shares of the life sciences company's stock, valued at approximately $5,325,000. Rubric Capital Management LP owned 0.38% of Integra LifeSciences at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock valued at $37,000 after purchasing an additional 425 shares during the last quarter. Blue Trust Inc. grew its position in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of Integra LifeSciences by 1.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company's stock valued at $1,764,000 after purchasing an additional 551 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra LifeSciences by 7.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company's stock valued at $421,000 after purchasing an additional 1,010 shares during the last quarter. Finally, KBC Group NV boosted its position in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after acquiring an additional 1,120 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Citigroup raised their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research report on Monday, October 7th. JMP Securities decreased their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating on the stock in a research report on Tuesday, July 30th. Finally, BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $24.00.

Integra LifeSciences Stock Up 3.5 %

Shares of NASDAQ:IART traded up $0.84 during midday trading on Wednesday, hitting $24.54. 523,591 shares of the company's stock traded hands, compared to its average volume of 1,091,270. The firm's fifty day moving average price is $20.35 and its two-hundred day moving average price is $24.00. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a market cap of $1.89 billion, a PE ratio of -270.75, a P/E/G ratio of 0.82 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.76 earnings per share. On average, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.